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Dr T. Bruce Ferguson (Greenville, NC). I would like to
congratulate Dr Kilic and his coauthors on an important study
using the National Inpatient Sample. This is something that we
have started doing more and more frequently, and this is an elegant
analysis using that rich data resource. As well, the findings of your
study are actually provocative in supporting something we have
suspected for some time, while also introducing some new
thoughts into the equation.The Journal of Thoracic and CaYou indicated in your paper and in the presentation that 30% of
the overall variability in cost is driven by the nature of the environ-
ment in which the services are delivered. You conclude that the
variability, by any criteria, is excessively high. This is a health pol-
icy issue that CMS would look at and say variability is bad, and we
need to figure out why.
The other part of your interesting data, however, focused on in-
hospital issues related to mortality, including sepsis and some
things we normally would not think of as necessarily driving
health care costs in coronary bypass surgery. It is not surprising
to me that the VAD patients and the ECMO patients generated
the highest costs, but, fortunately, they occur infrequently.
So, I have 2 questions for you, 1 in each area.
At the health policy level, if we as stewards of our specialty can
look and see that there is this huge variability in the cost of coro-
nary bypass surgery across this sampling of hospitals across the
country, what can we do at the specialty level that would generate
information at the health policy level that would reduce that level
of the variation and excess in health care costs?
And the second question is, in terms of the in-hospital mortal-
ity and the single greatest cause of morbidity, which is sepsis,
what could we do at the local level to be able to drive those costs
down? Can we fix sepsis by putting central lines in safely and
preventing pneumonia and doing MRSA screening and so forth?
Do we really think about reducing health care costs when we do
these things? And is there a point at which we say to a patient
who is going to die and their family, I am sorry, we cannot
really do anything else? Particularly when this occurs so
infrequently?
Your study is provocative in raising these 2 important issues.
Dr Kilic. Thank you, Dr Ferguson, for those comments and
questions. To address your first question about health policy impli-
cations, I think what this study does is really serves as a platform to
demonstrate statistically that there is a significant variability be-
tween institutions with respect to costs of CABG. The future steps
will be to identify specifically what processes of care are different
between those institutions, because what these data identify is that
there may be a comparable quality of care in terms of hard data,
such as mortality and morbidity, between institutions, but the path-
ways that are used to achieve that level of care are significantly
different, with significantly differing costs. So, what this does is
really just serves as a platform, and we need to do more investiga-
tion to figure out what the specific processes are that are contrib-
uting to these differing costs.
With respect to your second question about sepsis and mortal-
ity, again, when we are talking about evaluating providers or
evaluating programs, the gold standard should be the outcomes
and not surrogates for outcomes such as costs. So, I think the ul-
timate responsibility should be to provide good quality of care
with low mortality and low morbidity, and these data sort of
expectedly show that sepsis, which is going to result in prolonged
ICU stays and greater resource utilization, is a significant driver
of cost. That is not to say that we would not potentially be able to
look at how different institutions manage sepsis, their adherence
to clinical guidelines, to see if there is some type of divergence in
how those specific complications are managed to see if that may
be contributing to the differing costs as well, and I think the same
things apply for the in-hospital mortality.rdiovascular Surgery c Volume 147, Number 1 115
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DDr Ferguson. One of the implications of your data and study
in the health care environment, which is evolving in the United
States, is that providers are only going to get paid for better
quality care and lower-cost care. So, addressing both of those
issues is going to become important if we are going to reduce
the 30% variability across the providers; the alternative is
that there will be many fewer places doing coronary bypass
surgery.
Nice paper, and my congratulations to the authors.
Dr Kilic. Thank you.
Dr George Magovern (Pittsburgh, Pa). Would you further
define how you determined cost? Is cost a function of the charges
that a hospital agrees to or are they actual costs of the procedure?
Dr Kilic. Thank you for that question. The Nationwide Inpa-
tient Sample will actually provide the charges in the data set, and
the AHRQ has specific costtocharge ratios that they develop for
each individual hospital. So, utilizing that ratio, we are able
to derive actual costs, which we believe are a better reflection
of actual resource utilization versus the charges, which can
affect payer policies and other things not related to resource
utilization.
Dr Magovern. My second question is that as you decrease the
cost and increase the efficiency of coronary bypass surgery and
move it out into smaller hospitals, you also then make it more diffi-
cult to innovate or improve upon an operation. Specifically, how
will small-volume centers learn to do off-pump coronary surgery
or robotic coronary procedures?
In conclusion, most operative procedures evolve over time.
Thus, surgeons need to find a balance between lowering costs
and decreasing variability on one hand and improving outcomes116 The Journal of Thoracic and Cardiovascular Surgwith improvements in the operation with minimally invasive tech-
niques, robotics, etc.
Dr Kilic. That is an excellent point.
Dr Claudio Muneretto (Brescia, Italy). I congratulate the
authors for a nice paper. I did not find atrial fibrillation as a risk
factor for increasing cost. Many previous studies demonstrate
that atrial fibrillation made longer the stay in the hospital, made
higher the consultant cost for several physicians, and, in addition,
increases significantly stroke rate, renal failure, and low cardiac
syndrome. Could you comment on that?
Dr Kilic. That is a great question regarding atrial fibrillation
and why that was not depicted as a predictor of cost. We actually
did not include the individual diagnostic comorbidities in the
mixed-effect linear regression model. Instead, what we utilized
was the Charlson comorbidity score, which is a cumulative score
that incorporates all those comorbidities into one index. But, I
think it may be a good point to go and look back at the specific co-
morbidities and see which ones tend to be the drivers of cost.
Dr A. Pieter Kappetein (Rotterdam, The Netherlands). Thank
you much. Excellent paper. My question is also related to the
previous issue. Why did you use the Charlson comorbidity index
and not, for example, the STS score? Are there certain advantages
or disadvantages to one of these scores?
Dr Kilic. Ideally, we would like to use something like the STS
score. Unfortunately, many of those variables that are in the STS
CABG riskmodel are not available in the NIS registry. So, it would
just simply be a limitation of the database. But, again, I do think it
would be worth going back and looking at the specific comorbid-
ities and see if there are individual ones that seem to drive costs
more than the others.ery c January 2014
